PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
PTC Therapeutics (PTCT) Misses Q1 EPS by 32c, Revenues Beat
May 4, 2021 5:31 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.83), $0.32 worse than the analyst estimate of ($1.51). Revenue for the quarter came in at $117.94 million versus the consensus estimate of $98.8 million.
First Quarter 2021 Financial Highlights:
Total revenues were $117.9 million for the first quarter of 2021, compared to total revenues of $68.3 million for the first quarter of 2020, a 32% increase. Total revenue includes net product revenue of $91.3 million and collaboration and royalty revenue of $26.7 million in the first quarter of 2021.Translarna net product revenues were $46.5 million for the first quarter of 2021, compared to $40.5 million... More